Press Releases June 22, 2026 05:00 PM

ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of May 2026

ArrowMark Financial announces estimated Net Asset Value (NAV) of $21.10 as of May 31, 2026

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
BANX

ArrowMark Financial Corp., a NASDAQ-listed closed-end fund, released its estimated and unaudited Net Asset Value (NAV) as of May 31, 2026, reporting an NAV of $21.10. The fund primarily invests in regulatory capital securities of financial institutions to provide current income to shareholders. This NAV estimate is not a full financial statement and is subject to change. The announcement includes a summary of risk factors and directs investors to official filings for detailed information.

ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of May 2026
BANX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Estimated NAV as of May 31, 2026, is $21.10, reflecting the fund's current valuation.
  • ArrowMark Financial is a closed-end fund focused on investment in regulatory capital securities of financial institutions, targeting income generation.
  • Numerous risk factors affect the fund, including interest rate, liquidity, credit, and market risks, inherent to financial and banking sectors.

DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of May 31, 2026, was $21.10.

This estimated NAV is not a comprehensive statement of our financial condition or results for the month end.

About ArrowMark Financial Corp.
ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the symbol “BANX.” Its investment objective is to provide shareholders with current income. BANX pursues its objective by investing primarily in regulatory capital securities of financial institutions. BANX is managed by ArrowMark Asset Management, LLC. To learn more, visit ir.arrowmarkfinancialcorp.com, or contact Destra at 877.855.3434 or by email at [email protected].

Disclaimer and Risk Factors:
There is no assurance that ArrowMark Financial will achieve its investment objective. ArrowMark Financial is subject to numerous risks, including investment and market risks, management risk, income and interest rate risks, banking industry risks, preferred stock risk, convertible securities risk, debt securities risk, liquidity risk, valuation risk, leverage risk, non-diversification risk, credit and counterparty risks, market at a discount from net asset value risk and market disruption risk. Shares of closed-end investment companies may trade above (a premium) or below (a discount) their net asset value. Shares of ArrowMark Financial may not be appropriate for all investors. Investors should review and consider carefully ArrowMark Financial's investment objective, risks, charges and expenses. Past performance does not guarantee future results.

The Annual Report, Semi-Annual Report and other regulatory filings of the Company with the SEC are accessible on the SEC's website at www.sec.gov and on the BANX’s website at ir.arrowmarkfinancialcorp.com.

Contact:
[email protected]


Risks

  • Investment and market risks including exposure to financial institutions and regulatory capital securities could impact fund performance.
  • Liquidity and valuation risks associated with closed-end funds and market disruptions may cause shares to trade above or below NAV, affecting investor returns.
  • Interest rate and credit risks, inherent to debt and preferred securities held, present uncertainties in income and capital preservation.

More from Press Releases

Pricing of CNH Industrial Capital LLC $600 million notes Jun 22, 2026 SEACOR Marine Acknowledges Receipt of Letter by Shareholder Jun 22, 2026 MarketWise Announces Premier Partnership with USA Field Hockey Jun 22, 2026 FTI Consulting Strengthens Risk, Compliance & AI Advisory Capabilities in Australia With Appointment of Jerome Nyssen Jun 22, 2026 Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions Jun 22, 2026